
Maite Rio
639 posts

Maite Rio
@RrTechu
Neumóloga @neumologia_HUG. Prof. asociada UEM. Donde el aire escasea, busco respuestas.Foco en EPID, eco e hipertensión pulmonar como retos y motor de avance.
























💊🛡️🫁 Methotrexate & the RA Lung: Not the Villain after all? Systematic Review 🎯 Objectives •🔍 Assess progression of RA-ILD in patients exposed to methotrexate (MTX) •🫁 Evaluate lung involvement in RA patients without ILD who are exposed to MTX 🧪 Methods •📚 Systematic review of studies reporting MTX effects on ILD (primary or secondary endpoints) •👥 36,444 RA patients •💉 18,548 (50.8%) on MTX •🆚 Non-MTX users (N-MTX) used as controls in 14 studies 🔬 Lung assessment tools •🖥️ HRCT: 10 studies •🌬️ PFTs: 8 studies •🩸 ABG analysis: 1 study •⏳ Survival analysis: 5 studies 📌 Key Results 1️⃣ MTX & ILD Development •🛡️ 9 studies: MTX not associated with developing ILD 2️⃣ MTX & RA-ILD Progression •📘 5 studies: MTX not associated with ILD progression •⚠️ 1 study: Low-dose MTX → accelerated decline in lung function 3️⃣ Survival •💙 1 study: MTX group had better survival vs N-MTX 4️⃣ Acute Exacerbations •❗ 1 study: MTX significantly associated with acute ILD exacerbations 🧾 Conclusion MTX shows no overall association with increased risk or progression of ILD in RA patients. Conflicting findings exist regarding lung function decline and acute exacerbations, but the predominant evidence supports MTX safety in RA-ILD. #RheumattDoc #MedTwitter #BSR #RheumTwitter #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1 @nileshnolkha







El Hospital de Getafe mejora la asistencia de los pacientes con cáncer de pulmón y otras patologías respiratorias. cronicasanitaria.es/2025/11/06/el-…




